Is EVMN or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% Generate Biomedicines N/A N/A N/A

Does the media prefer EVMN or GENB?

In the previous week, Evommune had 4 more articles in the media than Generate Biomedicines. MarketBeat recorded 16 mentions for Evommune and 12 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of -0.15 beat Evommune's score of -0.44 indicating that Generate Biomedicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Generate Biomedicines 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EVMN or TSHA more profitable?

Taysha Gene Therapies' return on equity of -56.07% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% Taysha Gene Therapies N/A -56.07% -40.16%

Does the media refer more to EVMN or TSHA?

In the previous week, Evommune had 8 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 16 mentions for Evommune and 8 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of -0.06 beat Evommune's score of -0.44 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Taysha Gene Therapies 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, KARD or EVMN?

Kardigan has higher earnings, but lower revenue than Evommune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A N/A N/A N/A Evommune $13M 39.63 -$68.87M -$11.03 N/A

Is KARD or EVMN more profitable?

Kardigan's return on equity of 0.00% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Kardigan N/A N/A N/A Evommune N/A -62.63% -40.55%

Does the media refer more to KARD or EVMN?

In the previous week, Evommune had 13 more articles in the media than Kardigan. MarketBeat recorded 16 mentions for Evommune and 3 mentions for Kardigan. Kardigan's average media sentiment score of 0.04 beat Evommune's score of -0.44 indicating that Kardigan is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EVMN or ABCL?

In the previous week, AbCellera Biologics had 21 more articles in the media than Evommune. MarketBeat recorded 37 mentions for AbCellera Biologics and 16 mentions for Evommune. AbCellera Biologics' average media sentiment score of 0.43 beat Evommune's score of -0.44 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 10 Very Positive mention(s) 4 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to EVMN or SNDX?

In the previous week, Syndax Pharmaceuticals had 8 more articles in the media than Evommune. MarketBeat recorded 24 mentions for Syndax Pharmaceuticals and 16 mentions for Evommune. Syndax Pharmaceuticals' average media sentiment score of -0.12 beat Evommune's score of -0.44 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral

Evommune (EVMN) Competitors

$14.20 +0.13 (+0.90%)

Closing price 08/11/2026 03:59 PM Eastern

Extended Trading

$14.00 -0.20 (-1.39%)

As of 08:06 AM Eastern

Compare

EVMN vs. GENB, TSHA, KARD, ABCL, and SNDX

Should you buy Evommune stock or one of its competitors? Evommune's main competitors and comparable companies include Generate Biomedicines (GENB), Taysha Gene Therapies (TSHA), Kardigan (KARD), AbCellera Biologics (ABCL), and Syndax Pharmaceuticals (SNDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Evommune compare to Generate Biomedicines?

Evommune (NYSE:EVMN) and Generate Biomedicines (NASDAQ:GENB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Generate Biomedicines' return on equity of 0.00% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Generate Biomedicines	N/A	N/A	N/A

Evommune has higher earnings, but lower revenue than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	39.63	-$68.87M	-$11.03	N/A
Generate Biomedicines	$31.89M	57.43	-$203.15M	-$1.07	N/A

Evommune presently has a consensus price target of $43.25, suggesting a potential upside of 204.66%. Generate Biomedicines has a consensus price target of $25.40, suggesting a potential upside of 78.00%. Given Evommune's higher probable upside, research analysts clearly believe Evommune is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Evommune had 4 more articles in the media than Generate Biomedicines. MarketBeat recorded 16 mentions for Evommune and 12 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of -0.15 beat Evommune's score of -0.44 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Generate Biomedicines	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Generate Biomedicines beats Evommune on 7 of the 13 factors compared between the two stocks.

How does Evommune compare to Taysha Gene Therapies?

Evommune (NYSE:EVMN) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Evommune currently has a consensus price target of $43.25, suggesting a potential upside of 204.66%. Taysha Gene Therapies has a consensus price target of $12.77, suggesting a potential upside of 91.16%. Given Evommune's higher possible upside, equities analysts clearly believe Evommune is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Evommune has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	39.63	-$68.87M	-$11.03	N/A
Taysha Gene Therapies	$7.47M	256.94	-$109M	-$0.38	N/A

Taysha Gene Therapies' return on equity of -56.07% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

77.7% of Taysha Gene Therapies shares are held by institutional investors. 31.1% of Evommune shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Evommune had 8 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 16 mentions for Evommune and 8 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of -0.06 beat Evommune's score of -0.44 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Taysha Gene Therapies beats Evommune on 8 of the 14 factors compared between the two stocks.

How does Evommune compare to Kardigan?

Kardigan (NASDAQ:KARD) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Kardigan's return on equity of 0.00% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
Evommune	N/A	-62.63%	-40.55%

Kardigan currently has a consensus price target of $43.50, suggesting a potential upside of 97.19%. Evommune has a consensus price target of $43.25, suggesting a potential upside of 204.66%. Given Evommune's higher probable upside, analysts clearly believe Evommune is more favorable than Kardigan.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

In the previous week, Evommune had 13 more articles in the media than Kardigan. MarketBeat recorded 16 mentions for Evommune and 3 mentions for Kardigan. Kardigan's average media sentiment score of 0.04 beat Evommune's score of -0.44 indicating that Kardigan is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kardigan has higher earnings, but lower revenue than Evommune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	N/A	N/A	N/A
Evommune	$13M	39.63	-$68.87M	-$11.03	N/A

Summary

Evommune beats Kardigan on 5 of the 9 factors compared between the two stocks.

How does Evommune compare to AbCellera Biologics?

Evommune (NYSE:EVMN) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

61.4% of AbCellera Biologics shares are held by institutional investors. 31.1% of Evommune shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Evommune currently has a consensus price target of $43.25, indicating a potential upside of 204.66%. AbCellera Biologics has a consensus price target of $12.83, indicating a potential upside of 31.49%. Given Evommune's stronger consensus rating and higher possible upside, research analysts plainly believe Evommune is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Evommune has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	39.63	-$68.87M	-$11.03	N/A
AbCellera Biologics	$66.17M	45.22	-$146.41M	-$0.54	N/A

Evommune has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

In the previous week, AbCellera Biologics had 21 more articles in the media than Evommune. MarketBeat recorded 37 mentions for AbCellera Biologics and 16 mentions for Evommune. AbCellera Biologics' average media sentiment score of 0.43 beat Evommune's score of -0.44 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	10 Very Positive mention(s)	4 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Evommune and AbCellera Biologics tied by winning 8 of the 16 factors compared between the two stocks.

How does Evommune compare to Syndax Pharmaceuticals?

Evommune (NYSE:EVMN) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Evommune currently has a consensus price target of $43.25, suggesting a potential upside of 204.66%. Syndax Pharmaceuticals has a consensus price target of $41.91, suggesting a potential upside of 106.55%. Given Evommune's higher possible upside, research analysts plainly believe Evommune is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, Syndax Pharmaceuticals had 8 more articles in the media than Evommune. MarketBeat recorded 24 mentions for Syndax Pharmaceuticals and 16 mentions for Evommune. Syndax Pharmaceuticals' average media sentiment score of -0.12 beat Evommune's score of -0.44 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evommune has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Evommune's return on equity of -62.63% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Evommune has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	39.63	-$68.87M	-$11.03	N/A
Syndax Pharmaceuticals	$172.35M	10.43	-$285.42M	-$2.51	N/A

Summary

Evommune and Syndax Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Evommune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVMN vs. The Competition

Export

Metric	Evommune	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$510.63M	$3.71B	$7.08B	$24.25B
Dividend Yield	N/A	3.76%	2.58%	3.70%
P/E Ratio	-1.29	10.37	268.39	30.36
Price / Sales	39.63	1,227.72	573.03	68.34
Price / Cash	N/A	102.54	72.26	33.15
Price / Book	1.86	17.81	13.16	6.54
Net Income	-$68.87M	-$13.23M	$3.44B	$1.06B
7 Day Performance	9.34%	3.23%	2.09%	0.35%
1 Month Performance	7.33%	-1.13%	-0.25%	2.41%
1 Year Performance	N/A	59.42%	70.32%	18.19%

Evommune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVMN Evommune	2.6396 of 5 stars	$14.20 +0.9%	$43.25 +204.7%	N/A	$510.63M	$13M	N/A	45	Trending News Earnings Report Analyst Revision
GENB Generate Biomedicines	1.9621 of 5 stars	$13.89 -4.1%	$25.40 +82.9%	N/A	$1.86B	$31.89M	N/A	312	Earnings Report Analyst Revision
TSHA Taysha Gene Therapies	2.6682 of 5 stars	$6.34 -1.9%	$12.77 +101.4%	+142.0%	$1.86B	$9.77M	N/A	180	News Coverage Earnings Report
KARD Kardigan	4.3387 of 5 stars	$20.36 +0.5%	$43.50 +113.7%	N/A	$1.81B	N/A	N/A	N/A	News Coverage
ABCL AbCellera Biologics	2.9231 of 5 stars	$6.53 +10.3%	$9.40 +44.0%	+116.9%	$1.81B	$75.13M	N/A	500	Trending News Earnings Report Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EVMN) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evommune (EVMN) Competitors

EVMN vs. GENB, TSHA, KARD, ABCL, and SNDX

How does Evommune compare to Generate Biomedicines?

Summary

How does Evommune compare to Taysha Gene Therapies?

Summary

How does Evommune compare to Kardigan?

Summary

How does Evommune compare to AbCellera Biologics?

Summary

How does Evommune compare to Syndax Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evommune (EVMN) Competitors

EVMN vs. GENB, TSHA, KARD, ABCL, and SNDX

How does Evommune compare to Generate Biomedicines?

Is EVMN or GENB more profitable?

Which has stronger earnings and valuation, EVMN or GENB?

Do analysts rate EVMN or GENB?

Does the media prefer EVMN or GENB?

Summary

How does Evommune compare to Taysha Gene Therapies?

Do analysts rate EVMN or TSHA?

Which has preferable earnings & valuation, EVMN or TSHA?

Is EVMN or TSHA more profitable?

Do insiders & institutionals hold more shares of EVMN or TSHA?

Does the media refer more to EVMN or TSHA?

Summary

How does Evommune compare to Kardigan?

Is KARD or EVMN more profitable?

Do analysts prefer KARD or EVMN?

Does the media refer more to KARD or EVMN?

Which has preferable earnings and valuation, KARD or EVMN?

Summary

How does Evommune compare to AbCellera Biologics?

Do insiders & institutionals hold more shares of EVMN or ABCL?

Do analysts rate EVMN or ABCL?

Which has better earnings and valuation, EVMN or ABCL?

Is EVMN or ABCL more profitable?

Does the media favor EVMN or ABCL?

Summary

How does Evommune compare to Syndax Pharmaceuticals?

Do analysts prefer EVMN or SNDX?

Does the media refer more to EVMN or SNDX?

Is EVMN or SNDX more profitable?

Which has better valuation & earnings, EVMN or SNDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools